glp-1 and dopamine Emerging Nondopaminergic Medications for Parkinson's Disease: Focusing on A2A Receptor Antagonists GLP1 Receptor Agonists GIPR signaling reduces dopamine release

Injectable forms of GHK-Cu are used experimentally for systemic repair, though injectable GHK-Cu is not FDA-approved and carries potential risks

Beyond Ozempic , emerging therapies like AOD-9604 , 5-Amino-1MQ, CJC-1295, Ipamorelin, and MOTS-c are expanding our arsenal and giving patients options

Medications such as opioids that could further exacerbate clinical manifestation of gastroparesis should be avoided

3) has been associated with phosphorylation at 26 sites of tau protein, and its activity level correlates with the progression of the neurodegenerative process, and the over-activation of this enzyme contributes to tau hyper-phosphorylation (Yamaguchi et al., 1996

Interested in trying Glutathione IV Therapy